Danish researchers analyzed data from 77,000 adults using anti-obesity medications without diabetes. They found 52 percent quit within a year. Eighteen percent stopped within three months, 31 percent within six months, and 42 percent within nine months.
Adults under 30 were 48 percent more likely to stop than those aged 45 to 59. People living in low-income areas quit 14 percent more often than residents of wealthier neighborhoods. Men showed higher dropout rates than women.
Side Effects and Chronic Conditions Increase Dropouts
Researchers noted people with chronic health problems or prior gastrointestinal or psychiatric medication use stopped treatment more often. These patients likely experienced side effects such as nausea or vomiting.
High medication costs also contributed to early discontinuation. In Denmark, a month’s supply of Ozempic can reach €313, compared to €120 in Germany, unless patients qualify for government coverage.
GLP-1 Drugs Require Long-Term Use
Ozempic and Wegovy mimic a hormone that reduces appetite, helping people lose weight. If patients stop treatment, they often regain the lost weight.
Professor Reimar W. Thomsen of Aarhus University emphasized long-term adherence. “Stopping the medication eliminates all appetite control benefits,” he said.
Public Health Implications
Thomsen stressed the importance of supporting patients who benefit from these drugs. Studies show GLP-1 medications reduce risks of heart disease, cancer, and addiction.
“With over half of European adults overweight or obese, identifying patients who benefit from long-term interventions is critical,” Thomsen said. “Encouraging adherence improves health outcomes and quality of life.”
Researchers plan to present these findings at the European Association for the Study of Diabetes meeting in Vienna this week.
